Respana Therapeutics Inc.

Respana Therapeutics Overview

- Respana is developing a novel drug to combat excessive immune response
- Initial use in respiratory infections
- Experienced management team
- Majority of funding to date provided by the National Institutes of Health (NIH NIAID)
- Respana is raising a $1 million Seed round (Q4) and a $15 million Series A (2025) to generate significant value by the end of Phase I+ studies in 2027



The Problem

A *significant unmet medical need exists*:

- 5-6 million people die worldwide from respiratory infections each year
- The worst outcomes from respiratory illness are often caused by the immune response
- New and mutating viruses increase the numbers put at risk from respiratory illness
- Vaccines are only part of the solution – virus-specific, limited impact
- Most treatments today for advanced respiratory illness focus on supportive care and antibiotics – but many lives are still lost each year





Respana's Solution – Better Outcomes from Respiratory Infections

Respana's drug, RT-002, targets the complications caused by the immune response to the infection, not the infectious agent itself.

RT-002:

- *not pathogen-specific*; not limited by new viruses and new variants
- in our animal testing:
  - *increases survival*; 100% survival of humanized mice with influenza at 14 days compared to <25% survival in controls
  - *displays no toxic effects*
  - *facilitates healing and repair*; returns host to proper immune function

First Trial Success Creates Significant Pipeline

RT-002 can be first-in-class with several large-market therapeutic opportunities

Initial indication: Patients presenting at acute care hospital with progressive respiratory disease with suspected/confirmed influenza

Success in first-in-human (FIH) trials stimulates a pipeline for Respana and its future partners:

- Outpatient interventions with new formulations
- Multiple respiratory and non-respiratory illness indications

Intellectual Property

- Exclusive Licensee of patent “Compositions and methods for targeting of the surfactant protein A receptor” from the Penn State Research Foundation [US 10,077,309 (2018)]
- Drs. Zissis Chroneos and Neil Christensen (Respana co-founders) are the inventors and our partners on the NIH STTR awards
- Patents are issued across an extensive geography
- The patent includes claims related to compositions for prophylaxis, therapy, and diagnosis of conditions with macrophage-mediated immune response



Respana's Experienced Management Team

Kevin Harter, Chief Executive Officer

- Serial entrepreneur, substantial operating and business development experience, successful fund-raising history
- Chief Innovation Officer, Penn State College of Medicine; CEO, Saladax Biomedical; Co-Founder/SVP, Life Sciences Greenhouse; Co-Founder/COO, Keystone Medical Systems



Scott Willett, Ph.D., Chief Technology Officer

- 30+ years developing processes for clinical and commercial manufacture of recombinant proteins, including 5 years at Amgen
- Led development and manufacturing of PRM-151 (recombinant human pentraxin-2) over a 14-year span at Promedior, Inc. from early discovery through Phase III clinical testing resulting in sale of the company to Roche/Genentech

Jeremy Middleton, Chief Business Officer

- 35 years of biopharmaceutical executive experience holding senior leadership roles at large and entrepreneurial companies
- His experience includes: Elusys Therapeutics, Valera Pharmaceuticals, Neose Technologies; Global Product Director for Humira - developed strategic plan that led to Abbott acquisition



Development and Clinical Timeline Estimate

Respana Development Plan								
	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	Q3 26	Q4 26
IND- ENABLING ACTIVITIES								
KoL interactions about protocol aims								
Analytical Methods								
Upstream Process								
Downstream Process								
Formulation								
Manufacture								
Pre-IND Meeting								
IND-Enabling Studies								
IND Filing Prep								
IND Filing								
	Q1 27	Q2 27	Q3 27	Q4 27	Q1 28	Q2 28	Q3 28	Q4 28
HUMAN TRIALS								
Phase 1								
Phase 1a								
Phase 2								

Partnering

Use of Funds in Seed and Series A

Seed Round ($1MM) plus STTR award

- Research Cell Bank Complete
- Master Cell Bank Complete
- Expanded Team
- Pre-IND Meeting
- IP Extension and Expansion
- Extensive Business Development

2025: Series A ($15MM)

- cGMP Manufacturing
- IND-enabling Studies
- IND Filing
- First In Human Trials

2027 Exit/Strategic Partnership

- Sale or alliance with immunology / infectious disease pharma or biotech



Terms of Financing – Seed Round

Simple Agreement for Future Equity

- $1.0 million goal
- Investors in SAFE convert at the better of:
  - 20% discount to Series A
  - Valuation cap of $7 million

Respana Therapeutics: Summary

Novel therapeutic approach

- Targets *the host, not the pathogen*
- Works *upstream* of other limited therapeutic options

Strong and expanding IP position

Seasoned scientific and management teams

Highly promising preclinical data

Priority areas for Federal funding sources

Large, broad-based market opportunities

Cell line development nearing completion

Progress to date funded by grants and management team

Thank you.

Kevin Harter
kharter@respanatx.com
717-805-0379